---
title: "Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286313104.md"
description: "The Phase 2b study ACR-368, designed for registration purposes, is making progress with a simultaneous interim analysis and data refresh planned for both arms of all-comer (biopsy-independent) serous endometrial cancer in the latter part of 2026."
datetime: "2026-05-13T20:11:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286313104.md)
  - [en](https://longbridge.com/en/news/286313104.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286313104.md)
---

# Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

The Phase 2b study ACR-368, designed for registration purposes, is making progress with a simultaneous interim analysis and data refresh planned for both arms of all-comer (biopsy-independent) serous endometrial cancer in the latter part of 2026.

### Related Stocks

- [ACRV.US](https://longbridge.com/en/quote/ACRV.US.md)

## Related News & Research

- [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | AYTU Stock News](https://longbridge.com/en/news/286813229.md)
- [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)